live DC-tumor fusion vaccine

Live DC-tumor fusion vaccine is an autologous cellular cancer vaccine generated by ex vivo fusion of patient-derived dendritic cells (DCs) with whole tumor cells. The resultant fusion cells combine the antigen-presenting capabilities of DCs with the entire repertoire of tumor antigens, providing broad and personalized tumor antigen presentation. These fusion cells express both MHC class I and II, co-stimulatory molecules (CD80, CD86, ICAM-1), and migrate to lymph nodes where they activate both CD4+ and CD8+ T lymphocytes, generating strong and long-lasting tumor-specific cytotoxic T cell responses. The vaccine is designed to break tolerance to tumor-associated antigens and induce robust cellular immunity to a wide range of solid and hematological cancers. This platform can be further modified—for example, by incorporating adjuvants (such as CpG oligodeoxynucleotides) or using treated tumor cells to enhance immunogenicity and safety. The vaccine is generally manufactured on a per-patient basis and used in clinical and preclinical trials for melanoma, AML, glioblastoma, breast, lung, liver, prostate, ovarian, pancreatic, colorectal, and other cancers[1][2][3][4].

Other names

DC/tumor fusion vaccineDC-tumor FC vaccinedendritic cell-tumor fusion vaccine